RESEARCH ARTICLE

Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival

Yuichiro Kitagawa, Itta Kawamura, Keiko Suzuki, Hideshi Okada, Takuma Ishihara, Hiroyuki Tomita, Kodai Suzuki, Chihiro Takada, So Sampei, Soichiro Kano, Kohei Kondo, Hirotaka Asano, Yugo Wakayama, Ryosuke Kamidani, Yuki Kawasaki, Hirotsugu Fukuda, Ayane Nishio, Takahito Miyake, Tetsuya Fukuta, Ryu Yasuda, Hideaki Oiwa, Yoshinori Kakino, Nagisa Miyazaki, Takatomo Watanabe, Takahiro Yoshida, Tomoaki Doi, Akio Suzuki, Shoza Yoshida, Hitoshi Matsuo, Shinji Ogura

1 Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Japan, 2 Gifu Heart Center, Gifu, Japan, 3 Department of Pharmacy, Gifu University Hospital, Gifu, Japan, 4 Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan, 5 Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Japan, 6 Department of Abuse Prevention Emergency Medicine, Gifu University Graduate School of Medicine, Gifu, Japan, 7 Department of Internal Medicine, Asahi University School of Dentistry, Mizuho, Japan, 8 Department of Clinical Laboratory, Gifu University Hospital, Gifu, Japan

☯ These authors contributed equally to this work.
* hideshi@gifu-u.ac.jp

Abstract

Syndecan-1 is found in the endothelial glycocalyx and is released into the bloodstream during stressed conditions, including severe diseases such as acute kidney injury, chronic kidney disease, and cardiovascular disease. This study investigated the prognostic value of serum syndecan-1 concentration in patients with heart failure upon admission. Serum syndecan-1 concentration was analyzed in 152 patients who were hospitalized for worsening heart failure from September 2017 to June 2018. The primary outcome of the study was readmission-free survival, defined as the time from the first admission to readmission for worsened heart failure or death from any cause, which was assessed at 30 months after discharge from the hospital. The secondary outcome of the study was survival time. Blood samples and echocardiogram data were analyzed. Univariate and multivariable time-dependent Cox regression analyses adjusted for age, creatinine levels, and use of antibiotics were conducted. The serum syndecan-1 concentration was significantly associated with readmission-free survival. Subsequently, the syndecan-1 concentration may have gradually decreased with treatment. The administration of human atrial natriuretic peptide and antibiotics may have modified the relationship between readmission-free survival and serum syndecan-1 concentration (p = 0.01 and 0.008, respectively). Serum syndecan-1 concentrations, which may indicate injury to the endothelial glycocalyx, predict readmission-free survival in patients with heart failure.
Introduction

 Decompensated heart failure is defined as a clinical syndrome in which a structural or functional change in the heart leads to its inability to eject and/or accommodate blood within the physiological pressure levels [1]. As the pathophysiology of decompensated heart failure is complicated and heterogeneous [2], an accurate assessment of severity remains a significant challenge. It is important to predict the prognosis of patients with heart failure to provide precise medical care.

 Currently, risk stratification of patients with non-ischemic heart failure is commonly based on clinical parameters, such as the New York Heart Association class; echocardiographic parameters, such as left ventricular ejection fraction (LVEF); and blood markers, such as the level of a 76-amino acid N-terminal fragment in the prohormone called B-type natriuretic peptide and brain natriuretic peptide [3, 4]. However, the use of plasma brain natriuretic peptide, while very valuable in differentiating heart failure from noncardiac causes of acute dyspnea [5], is debatable as a prognostic marker [6–8]. Currently, there is no class I indication in the guidelines for the use of specific biomarkers for prognostic purposes [9, 10].

 Pleural effusions are commonly recognized in patients with congestive heart failure. Transudative pleural effusion is caused by various factors such as increasing capillary hydrostatic pressure or decreasing colloid oncotic pressure.

 The sugar–protein glycocalyx covers the surface of a healthy vascular endothelium [11–13] and maintains vascular homeostasis, such as by regulating an oncotic gradient across the endothelial barrier [14–18]. The endothelial glycocalyx may get injured under abnormal conditions such as sepsis, diabetes, and hypertension, thereby increasing vascular permeability [15, 19, 20]. The removal of glycocalyx has been known to cause a dramatic increase in hydraulic permeability [21]. Furthermore, previous studies have found that rapid plasma volume expansion injured the endothelial glycocalyx [22].

 The endothelial glycocalyx consists of cell-bound proteoglycans, glycosaminoglycan side chains, and sialoproteins [23–25]. Proteoglycans are composed of a core protein, such as a syndecan family protein, to which glycosaminoglycan is linked. Syndecan-1 is the core protein in heparan sulfate proteoglycan, which is also found in the endothelial glycocalyx. Syndecan-1 detaches from the endothelium upon glycocalyx injury, thereby increasing its serum concentration [26]. Therefore, serum syndecan-1 has been used as a marker of endothelial injury in recent clinical studies [27, 28]. Because the pulmonary capillary glycocalyx is thinner than other organs [29], it may be easily injured by excess fluid. Therefore, transudative pleural effusion may occur due to heart failure. Moreover, the concentration of serum syndecan-1 has been found to be associated with clinical outcomes in patients with heart failure and preserved ejection fraction [30]. Additionally, it has been suggested that syndecan-1 is associated with left ventricular hypertrophy in heart failure with preserved ejection fraction [31].

 Therefore, in this study, we investigated the prognostic value of serum syndecan-1 concentration upon admission in patients with heart failure.

 Materials and methods

 Patient profile

 Patients who were hospitalized at Gifu Heart Center due to worsening heart failure between September 2017 and June 2018 were included in this study. Those who were <20 years old and/or had acute coronary syndrome, malignant tumor, liver cirrhosis, collagen disease, and hemodialysis were excluded from the analysis. Overall, 152 patients were enrolled in this study, and 784 samples were obtained.
Data collection and study design

Demographic and clinical data, including medical and medication histories, were collected. The following data were included in the time-dependent Cox regression model: age, sex, serum albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, blood urea nitrogen (BUN), creatinine (Cre) concentration, sodium, potassium, chlorine, C-reactive protein, estimated glomerular filtration rate (eGFR), white blood cell number, hemoglobin (Hb) concentration, hematocrit (Ht), hemoglobin A1c, left ventricular diastolic diameter (LVDd), left ventricular systolic diameter (LVDs), interventricular septum thickness (IVST), posterior wall thickness (PWT), LVEF, left atrial dimension (LAD), left atrial volume index (LAVI), and the diameter of the inferior vena cava (IVC).

Echocardiography was performed at the time of admission. Blood samples were obtained when the physician deemed it necessary, and they were collected into the sample collection tube with a serum separating medium. The serum was collected and preserved in a freezer at −80 °C. Serum syndecan-1 concentrations were measured using enzyme-linked immunosorbent assay (950.640.192, Diaclone, Besancon, Cedex, France). Sequential samples from the same patient were examined in the same enzyme-linked immunosorbent assay plate to avoid inter-assay variability. The primary outcome of the study was readmission-free survival, defined as the time from the first admission to readmission for worsened heart failure or death from any cause, which was assessed at 30 months after discharge from the hospital. The secondary outcome of the study was survival time.

Statistical analyses

Descriptive statistics are presented as frequencies and percentages for categorical variables and as medians with interquartile ranges for continuous variables. For the time-to-event analyses, enrolled patients were monitored from the study initiation until December 2019. Cumulative readmission-free survival rates, stratified by median of serum syndecan-1 concentration at baseline, were obtained with Kaplan–Meier estimation. To assess the effect of serum syndecan-1 concentration on readmission-free survival time and mortality, time-dependent Cox proportional hazards multivariable regression analyses were performed. Covariates in the model, including age [32, 33], Cre [33–36], and antibiotic use, indicating the presence of an infectious disease [18, 27, 28, 37], were selected a priori for their clinical relevance. Serum syndecan-1 concentration, Cre, and antibiotic use were treated as time-dependent covariates in the model. Additionally, serum syndecan-1 concentration was modeled using a restricted cubic spline to allow for nonlinear associations.

Furthermore, to assess whether the effects of serum syndecan-1 concentration were modified by blood and echocardiogram parameters, a cross-product term between serum syndecan-1 concentration and variables of parameters was included in the time-dependent Cox regression (i.e., interaction) analysis. A two-sided significance level of 0.05 was used for all statistical inferences. All data analyses were performed using the R statistical software, version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).

Ethics statement

The investigation conformed with the principles outlined in the Declaration of Helsinki [38]. Ethics approval was obtained from the medical ethics committee of Gifu University Graduate School of Medicine, Gifu, Japan (record no.: 29–216), and Gifu Heart Center, Gifu, Japan.
(record no.: 2017022). All patients provided written informed consent for their participation in the study as well as for the publication of this report.

**Results**

**Patient characteristics**

The demographic data of patients are presented in Table 1. Altogether, 152 patients (94 men and 58 women) with a median age of 76 (range, 68–85) years were enrolled in the study. These patients had basal heart disease, and all patients received medications, including various combinations. Differences in syndecan-1 concentrations among patients with different origins of heart failure are shown in S1 Table and those among patients with heart failure due to different medications are shown in S2 Table.

**Serum syndecan-1 and readmission-free survival in patients with heart failure**

The Kaplan–Meier curve showed that the median readmission-free survival time, stratified by median of serum syndecan-1 concentration at baseline, was 331 (<33.48 ng/mL) and 239 (≥33.48 ng/mL) days (Fig 1). The median readmission-free survival time of all patients was 288 days (event number = 67, 95% confidence interval [CI]: 227–356). Univariate and multivariable time-dependent Cox regression analyses adjusted for age, Cre, and antibiotic use, excluding the effect of infection, were conducted (Table 2 and Fig 2). We evaluated the effect on readmission-free survival using hazard ratios (HRs) when the value of serum syndecan-1 concentration changed from median among all data including repeated measurements (37.04 ng/mL) to 50 ng/mL, 100 ng/mL, 200 ng/mL, 300 ng/mL, and 400 ng/mL. With a change in serum syndecan-1 concentration from 37.04 ng/mL to 300 ng/mL, the unadjusted time-dependent Cox proportional hazards model revealed an association between serum syndecan-1 concentration and readmission-free survival (HR, 1.687; 95% CI, 1.1–2.585; p = 0.016). The analysis adjusted for covariates also showed that the serum syndecan-1 concentration was associated with readmission-free survival (HR, 1.865; 95% CI, 1.169–2.974; p = 0.009). The increase in serum syndecan-1 concentration from 37.04 ng/mL to 300 ng/mL was associated with an approximately 1.9-fold increase in the risk of readmission-free survival after adjusting for confounders.

The average concentration of syndecan-1 in serum was 72.4 ng/mL (95% CI, 37.5–107.2) upon admission, which peaked at 101.21 ng/mL (95% CI, 69.77–132.66 ng/mL) at 2.77 days after admission. Subsequently, the syndecan-1 concentration decreased gradually, probably as a result of treatment (Fig 3).

Table 3 shows the p-values for interaction of the parameters modifying the relationship between readmission-free survival and serum syndecan-1 concentration. The administration of human atrial natriuretic peptide and antibiotics appeared to modify the relationship between readmission-free survival and serum syndecan-1 concentration (p for interaction = 0.01 and 0.008, respectively; Fig 4). Moreover, AST, ALT, CK, BUN, Hb, Ht, PWT, and LAVI appeared to modify the relationship due to heart failure (p for interaction, 0.021, 0.001, <0.001, 0.003, 0.014, 0.004, 0.045, and 0.031, respectively; Fig 4 and S1 Fig). Likewise, BUN/Cre appeared to modify the relationship due to heart failure (S3 Table). Conversely, the LVEF did not appear to modify the relationship between readmission-free survival and serum syndecan-1 concentration (p for interaction = 0.418).
Table 1. Patients’ demographics.

| Characteristics                                      | N = 152 |
|------------------------------------------------------|---------|
| Age (years), median (IQR)                            | 76 (68–85) |
| Sex (Female/Male), n (%)                              | 58 (38.2) / 94 (61.8) |
| Follow-up time per patient (days), median (IQR)      | 23 (11–230) |
| Number of measurements per patient, median (IQR)     | 4 (3–6) |
| Death, n (%)                                         | 21 (13.8) |
| Readmission, n (%)                                   | 46 (30.3) |
| Basal heart disease, n (%)                           |         |
| Hypertensive heart disease                           | 26 (17.1) |
| Ischemic heart disease (post-PCI)                    | 21 (13.8) |
| Ischemic heart disease (post-CABG)                   | 12 (8.9) |
| Ischemic heart disease (conservative treatment)      | 7 (4.6) |
| Arrhythmia (tachycardia)                             | 20 (13.2) |
| Arrhythmia (bradycardia)                             | 1 (0.7) |
| Dilated cardiomyopathy                               | 17 (11.2) |
| Hypertrophic cardiomyopathy                          | 5 (3.3) |
| Other cardiomyopathy                                | 6 (4.0) |
| Aortic valve stenosis (post-operation)               | 6 (4.0) |
| Aortic valve insufficiency (post-operation)          | 3 (2.0) |
| Aortic valve insufficiency (conservative treatment)  | 1 (0.7) |
| Aortic valve insufficiency (conservative treatment)  | 5 (3.3) |
| Mitral valve insufficiency (post-operation)          | 3 (2.0) |
| Mitral valve insufficiency (conservative treatment)  | 8 (5.3) |
| Tricuspid valve insufficiency (conservative treatment)| 3 (2.0) |
| Congestive disease                                   | 2 (1.3) |
| Other                                                | 6 (3.9) |
| Medication, n (%)                                    |         |
| Beta blocker                                         | 123 (80.9) |
| ACE inhibitor/ARB                                    | 100 (65.8) |
| Statin                                               | 61 (40.1) |
| Antiplatelet                                         | 65 (42.8) |
| Anticoagulant                                        | 76 (50.0) |
| Loop diuretic                                        | 136 (89.5) |
| Spironolactone                                       | 100 (65.8) |
| Tolvaptan                                            | 60 (39.5) |
| Catecholamine                                        | 23 (15.1) |
| Human atrial natriuretic peptide                     | 96 (63.2) |
| Antibiotic                                           | 43 (28.3) |
| Echocardiographic characteristics, median (IQR)      |         |
| LVDd (mm)                                            | 53.2 (46.0–58.1) |
| LVDs (mm)                                            | 41.4 (30.4–51.0) |
| IVST (mm)                                            | 9.0 (8.3–9.7) |
| PWT (mm)                                             | 9.3 (8.4–10.2) |
| LVEF (%)                                              | 40.5 (25.6–59.6) |
| LAD (mm)                                             | 46.7 (43.7–52.0) |
| LAVI                                                 | 60.2 (47.4–67.7) |
| IVC (mm)                                             | 8.6 (6.4–12.1) |

IQR: interquartile range, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blocker, LVDd: left ventricular diastolic diameter, LVDs: left ventricular systolic diameter, IVST: interventricular septum thickness, PWT: posterior wall thickness, LVEF: left ventricular ejection fraction, LAD: left atrial dimension, LAVI: left atrial volume index, IVC: diameter of the inferior vena cava.

https://doi.org/10.1371/journal.pone.0260350.t001
Discussion

The present study revealed that serum syndecan-1 concentration: 1) was higher in patients with heart failure than in healthy subjects from previous reports [33], 2) responded promptly to treatment against heart failure, and 3) might predict readmission-free survival in patients with heart failure.

Serum syndecan-1 concentration in heart failure

A previous study has also reported that syndecan-1 concentration was associated with clinical outcomes in patients with heart failure and with preserved ejection fraction [30]. The serum syndecan-1 concentration in patients with heart failure in this study was 72.4 ng/mL at admission, which peaked to 101.21 ng/mL on day 3 of admission. Although values are higher than those reported in our previous studies, where the serum syndecan-1 concentration was 13.7–27.3 ng/mL in healthy individuals [33], the origin of syndecan-1 remains controversial.
Serum syndecan-1 concentration responded promptly to treatment

Syndecan-1 exists on the surface of several cell types [39–41]. A previous report has revealed that tissue syndecan-1 expression was associated with cardiac fibrosis [42]. However, the present study indicated that syndecan-1 concentration gradually decreased after admission with treatment. If syndecan-1 is the marker of fibrosis, syndecan-1 concentration should not decrease promptly with treatment.

Table 2. The relationship between serum syndecan-1 concentration and readmission/death.

|                   | Univariate analysis |                | Multivariable analysis |                |
|-------------------|---------------------|----------------|------------------------|----------------|
|                   | HR                  | 95% CI         | P value                | HR             | 95% CI         | P value    |
| Syndecan-1 (ng/mL) | 0.981               | 0.85–1.133     | 0.798                  | 1              | 0.873–1.145    | >0.999     |
| 37.04 (median)–50 |                     |                |                        |                |                |            |
| Syndecan-1 (ng/mL) | 0.994               | 0.631–1.567    | 0.981                  | 1.061          | 0.691–1.629    | 0.787      |
| 37.04 (median)–100 |                     |                |                        |                |                |            |
| Syndecan-1 (ng/mL) | 1.271               | 0.796–2.03     | 0.316                  | 1.388          | 0.875–2.204    | 0.164      |
| 37.04 (median)–200 |                     |                |                        |                |                |            |
| Syndecan-1 (ng/mL) | 1.687               | 1.1–2.585      | 0.016                  | 1.865          | 1.169–2.974    | 0.009      |
| 37.04 (median)–300 |                     |                |                        |                |                |            |
| Syndecan-1 (ng/mL) | 2.238               | 1.423–3.521    | <0.001                 | 2.504          | 1.457–4.305    | 0.001      |
| 37.04 (median)–400 |                     |                |                        |                |                |            |
| Age (years)       | 1.015               | 0.994–1.038    | 0.168                  | 1.011          | 0.989–1.033    | 0.336      |
| Sex (Male)        | 0.673               | 0.417–1.088    | 0.106                  | 0.644          | 0.382–1.087    | 0.099      |
| Creatinine (mg/dL)| 1.424               | 1.054–1.924    | 0.021                  | 1.442          | 1.059–1.964    | 0.02       |
| Antibiotics (Yes/No) | 1.051            | 0.372–2.968    | 0.925                  | 0.892          | 0.309–2.574    | 0.833      |
| Sodium (mEq/L)    | 1.038               | 0.958–1.124    | 0.363                  | -              | -              |            |
| eGFR (mL/min/1.73m)| 0.989               | 0.973–1.006    | 0.212                  | -              | -              |            |
| Hb (g/dL)         | 0.95                | 0.84–1.075     | 0.417                  | -              | -              |            |

HR: hazard ratio, CI: confidence interval, eGFR: estimated glomerular filtration rate, Hb: hemoglobin

Fig 2. The relationship between serum syndecan-1 concentration and readmission-free survival. Univariate and multivariable time-dependent Cox regression model adjusted for age, creatinine (Cre), and antibiotic use. (A) The unadjusted time-dependent Cox proportional hazards model. Serum syndecan-1 concentration is associated with readmission-free survival (hazard ratio [HR] for 300 ng/mL of serum syndecan-1 to median, 1.687; 95% confidence interval [CI], 1.1–2.585, p = 0.016). (B) The multivariable time-dependent Cox proportional hazards model. Serum syndecan-1 concentration is associated with readmission-free survival even after adjusting for covariates (HR for 300 ng/mL of serum syndecan-1 to median: 1.865, 95% CI: 1.169–2.974, p = 0.009).
Conversely, syndecan-1 exists on the surface of systemic vascular endothelial cells and may be released into the serum because of various reasons [41, 43]. Because rapid expansion of plasma volume causes injury to the endothelial glycocalyx [22], syndecan-1, a core protein of the endothelial glycocalyx, may be released into the serum, thereby increasing its concentration in circulation. Moreover, because the turnover of syndecan-1 expression on the pulmonary capillaries is rapid [44], its concentration may sharply increase in the systemic fluid volume. In brief, syndecan-1 may be a perceptive marker for assessing the state of volume overload through the state of heart failure. Achieving readmission-free survival for patients with heart failure with high syndecan-1 concentration was simple in the present study because the systemic fluid volume was abundant, despite the patients having received the treatment.

**Serum syndecan-1 concentration and readmission-free survival**

Several factors modified the relationship between readmission-free survival and serum syndecan-1 concentration. Increased syndecan-1 concentration after administration of hANP may indicate unsatisfactory control of congestion. Using antibiotics may pose complications of
Table 3. Predictors for readmission/death interacting with syndecan-1.

| Predictor names                          | p for interaction |
|-----------------------------------------|-------------------|
| Beta blockers                           | 0.885             |
| ACE inhibitor/ARB                       | 0.661             |
| Statins                                 | 0.495             |
| Antiplatelets                           | 0.161             |
| Anticoagulants                          | 0.895             |
| Loop diuretics                          | 0.248             |
| Spironolactone                          | 0.021             |
| Tolvaptan                               | 0.205             |
| Catecholamine                           | 0.175             |
| Human atrial natriuretic peptide        | 0.007             |
| Antibiotics                             | 0.008             |
| Albumin                                 | 0.476             |
| Aspartate aminotransferase              | 0.023             |
| Alanine transaminase                    | 0.002             |
| Creatinine kinase                       | <0.001            |
| Triglyceride                            | 0.995             |
| Total cholesterol                       | 0.485             |
| High density lipoprotein-cholesterol    | 0.576             |
| Low density lipoprotein-cholesterol     | 0.605             |
| Blood urea nitrogen                     | <0.001            |
| Creatinine                              | 0.016             |
| Sodium                                  | 0.073             |
| Potassium                               | 0.325             |
| Chlorine                                | 0.383             |
| C-reactive protein                      | 0.262             |
| Estimated glomerular filtration rate    | 0.244             |
| White blood cells number                | 0.12              |
| Hemoglobin concentration                | 0.009             |
| Hematocrit                              | 0.005             |
| Hemoglobin A1c                          | 0.788             |
| LVDD                                    | 0.841             |
| LVDS                                    | 0.685             |
| IVST                                    | 0.51              |
| PWT                                     | 0.03              |
| LVEF                                    | 0.418             |
| LAD                                     | 0.39              |
| LAVI                                    | 0.026             |
| IVC                                     | 0.284             |

ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blocker, LVDD: left ventricular diastolic diameter, LVDS: left ventricular systolic diameter, IVST: interventricular septum thickness, PWT: posterior wall thickness, LVEF: left ventricular ejection fraction, LAD: left atrial dimension, LAVI: left atrial volume index, IVC: diameter of the inferior vena cava.

https://doi.org/10.1371/journal.pone.0260350.t003

Infection such as pneumonia. Moreover, increased ALT and AST concentrations may represent congestive hepatopathy.

Low CK and BUN concentrations also appeared to modify the relationship due to heart failure in patients with low syndecan-1 concentration. These parameters may indicate low
nutrition status. Patients with heart failure often suffer from muscle atrophy because of chronic low nutrition and frailty [45]. In fact, muscle weakness reportedly affects the prognosis and progression of cardiovascular disease [46]. These results suggest that low nutrition status and excess fluid volume worsen the prognosis of heart failure.

The present study also showed that Hb and Ht modified the relationship between readmission-free survival and serum syndecan-1 concentration. This may be because the hemoconcentration increased wall shear stress and degraded endothelial glycocalyx [47, 48], which were related to syndecan-1 concentrations [33].

Moreover, echocardiography revealed that PWT and LAVI modified the relationship between readmission-free survival and serum syndecan-1 concentration. We believe that these
parameters have a direct relationship with heart failure. Left ventricular hypertrophy has a strong relationship with cardiovascular events such as myocardial infarction and sudden death [49, 50]. Increase in LAVI indicates a complication in atrial fibrillation, which can lead to heart failure and vice versa [51].

Here, we used the time-dependent Cox regression model to account for multiple measurements on a person [52]. This model is an extension of the Cox regression model that only considers risk factors at baseline. Hence, the time-dependent Cox model has the advantage of being able to assess risk posed by syndecan-1 concentration at each measurement point. Specifically, it allows us to assess the association between outcome (readmission or death) at the next measurement and syndecan-1 concentration at the previous measurement at each measurement point.

**Limitations**

As a limitation of the present work, the patients included in the study were not classified according to the New York Heart Association functional classification. However, our aim was not to create a diagnostic model but to evaluate the association between syndecan-1 concentration and outcome. In addition, the sample size was small, and data were obtained from a single institution. Therefore, further large scale studies are needed to confirm our findings.

**Conclusions**

In conclusion, serum syndecan-1 concentrations, which may indicate injury to the endothelial glycocalyx, can predict readmission-free survival in patients with heart failure. Additionally, the syndecan-1 concentration may be a fluid volume marker for heart failure and may be useful in its management.

**Supporting information**

S1 Fig. Age and sex appeared to modify the relationship due to heart failure.

(TIF)

S1 Table. Basal heart disease.

(DOCX)

S2 Table. Medication.

(DOCX)

S3 Table. The association between BUN/Cre and syndecan-1 concentration.

(DOCX)

**Acknowledgments**

We thank Yasuko Nogaki and Shoko Kumazaki for their technical assistance. We would like to thank Editage (www.editage.com) for English language editing.

**Author Contributions**

**Conceptualization:** Yuichiro Kitagawa, Itta Kawamura, Hideshi Okada, Kodai Suzuki, Shozo Yoshida.

**Data curation:** Itta Kawamura, Keiko Suzuki, Akio Suzuki.

**Formal analysis:** Takuma Ishihara, Akio Suzuki.
**Funding acquisition:** Yuichiro Kitagawa, Hideshi Okada, Kodai Suzuki, Tetsuya Fukuta, Ryu Yasuda, Yoshinori Kakino, Takahiro Yoshida, Tomoaki Doi, Shozo Yoshida, Shinji Ogura.

**Investigation:** Chihiro Takada, So Sampei, Soichiro Kano, Kohei Kondo, Hirotaka Asano, Yugo Wakayama, Ryo Kamidani, Ayane Nishio, Takahito Miyake, Tetsuya Fukuta, Ryu Yasuda, Yoshinori Kakino, Nagisa Miyazaki, Takatomo Watanabe, Tomoaki Doi, Akio Suzuki.

**Methodology:** Keiko Suzuki, Hiroyuki Tomita, Nagisa Miyazaki.

**Supervision:** Hitoshi Matsuo, Shinji Ogura.

**Writing – original draft:** Yuichiro Kitagawa.

**Writing – review & editing:** Hideshi Okada, Hiroyuki Tomita, Kodai Suzuki, Takahiro Yoshida, Tomoaki Doi, Akio Suzuki, Shozo Yoshida.

**References**

1. Mangini S, Pires PV, Braga FG, Bacal F. Decompensated heart failure. Einstein (Sao Paulo). 2013; 11(3):383–91. Epub 2013/10/19. https://doi.org/10.1590/s1679-45082013000300022 PMID: 24136770.

2. Joseph SM, Cedars AM, Ewald GA, Geltman EM, Mann DL. Acute decompensated heart failure: contemporary medical management. Tex Heart Inst J. 2009; 36(6):510–20. Epub 2010/01/14. PMID: 20069075.

3. Kalogeropoulos AP, Georgiopoulou VV, Butler J. Clinical adoption of prognostic biomarkers: the case for heart failure. Prog Cardiovasc Dis. 2012; 55(1):3–13. Epub 2012/07/25. https://doi.org/10.1016/j.pcad.2012.05.004 PMID: 22824105.

4. Motiwala SR, Januzzi JL Jr. Using biomarkers to “guide” heart failure management: current perspectives and future directions. Cardiol Rev. 2013; 21(3):127–34. Epub 2012/10/04. https://doi.org/10.1097/CRD.0b013e3182769073 PMID: 23032578.

5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Holland J, Dellinger EP, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347(3):161–7. Epub 2002/07/19. https://doi.org/10.1056/NEJMoa022333 PMID: 12124404.

6. Bettencourt P, Azevedo A, Pimenta J, Frioles F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; 110(15):2168–74. Epub 2004/09/29. https://doi.org/10.1161/01.CIR.0000144310.04433.BE PMID: 15451800.

7. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36(5):1587–93. Epub 2000/11/18. https://doi.org/10.1016/s0735-1097(00)00912-8 PMID: 11079662.

8. Nakada Y, Kawakami R, Nakano T, Takitsume A, Nakagawa H, Ueda T, et al. Sex differences in clinical characteristics and long-term outcome in acute decompensated heart failure patients with preserved and reduced ejection fraction. Am J Physiol Heart Circ Physiol. 2016; 310(7):H813–20. Epub 2016/01/10. https://doi.org/10.1152/ajpheart.00602.2015 PMID: 26747499.

9. Nakada Y, Kawakami R, Matsui M, Ueda T, Nakano T, Nakagawa H, et al. Value of Placental Growth Factor as a Predictor of Adverse Events During the Acute Phase of Acute Decompensated Heart Failure. Circ J. 2019; 83(2):395–400. Epub 2018/12/28. https://doi.org/10.1253/circj.CJ-18-0523 PMID: 30587700.

10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJF, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27):2129–200. Epub 2016/05/22. https://doi.org/10.1093/eurheartj/ehw128 PMID: 27206819.

11. Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red. Fed Proc. 1966; 25(6):1773–83. Epub 1966/11/01. PMID: 5927412.

12. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010; 105(6):687–701. Epub 2010/09/23. https://doi.org/10.1007/s00395-010-0118-z PMID: 20859744.
13. Rehm M, Zahler S, Lotsch M, Welsch U, Conzen P, Jacob M, et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology. 2004; 100(5):1211–23. https://doi.org/10.1097/00000542-200405000-00025 PMID: 15114220.

14. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012; 108(3):384–94. Epub 2012/02/01. https://doi.org/10.1093/bja/aer515 PMID: 22290457.

15. Frati-Munari AC. [Medical significance of endothelial glycocalyx]. Arch Cardiol Mex. 2013; 83(4):303–12. Epub 2013/11/28. https://doi.org/10.1016/j.acmx.2013.04.015 PMID: 24280179.

16. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med. 2010; 363(7):689–91. Epub 2010/09/08. https://doi.org/10.1056/NEJMci1007320 PMID: 20818861.

17. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007; 454(3):345–59. Epub 2007/01/27. https://doi.org/10.1007/s00424-007-0212-8 PMID: 17256154.

18. Chelazzi C, Villa G, Mancinelli P, De Gaudio AR, Adembri C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015; 19:26. Epub 2015/04/19. https://doi.org/10.1186/s13054-015-0741-z PMID: 25887223.

19. Henrich M, Guuss M, Weigand MA. Sepsis-induced degradation of endothelial glycocalyx. Scientific WorldJournal. 2010; 10:917–23. Epub 2010/05/25. https://doi.org/10.1100/tsw.2010.88 PMID: 20495770.

20. Okada H, Takegawa M, Suzuki K, Oda K, Takada C, Hotta Y, et al. Three-dimensional ultrastructure of capillary endothelial glycocalyx under normal and experimental endotoxemic conditions. Crit Care. 2017; 21(1):261. Epub 2017/10/24. https://doi.org/10.1186/s13054-017-1841-8 PMID: 29058634.

21. Berg S, Golster M, Lisander B. Albumin extravasation and tissue washout of hyaluronan after plasma volume expansion with crystalloid or hypooncotic colloid solutions. Acta Anaesthesiol Scand. 2002; 46 (2):166–72. Epub 2002/04/11. https://doi.org/10.1034/j.1399-6576.2002.460207.x PMID: 11942864.

22. Zhang X, Adamson RH, Curry FR, Weinbaum S. A 1-D model to explore the effects of tissue loading and tissue concentration gradients in the revised Starling principle. Am J Physiol Heart Circ Physiol. 2006; 291(6):H2950–64. https://doi.org/10.1152/ajpheart.01160.2005 PMID: 16905594.

23. Berg S, Golster M, Lisander B. Albumin extravasation and tissue washout of hyaluronan after plasma volume expansion with crystalloid or hypooncotic colloid solutions. Acta Anaesthesiol Scand. 2002; 46 (2):166–72. Epub 2002/04/11. https://doi.org/10.1034/j.1399-6576.2002.460207.x PMID: 11942864.

24. Li L, Ly M, Linhardt RJ. Proteoglycan sequence. Mol Biosyst. 2012; 8(6):1613–25. Epub 2012/04/20. https://doi.org/10.1039/c2mb25021g PMID: 22513887.

25. Salomon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol. 2012; 226(4):562–74. Epub 2011/11/22. https://doi.org/10.1002/path.3964 PMID: 22102407.

26. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007; 116(17):1896–906. Epub 2007/10/10. https://doi.org/10.1161/CIRCULATIONAHA.110.684852 PMID: 17923576.

27. Ostrowski SR, Haase N, Muller RB, Moller MH, Pott FC, Perner A, et al. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study. Crit Care. 2015; 19:191. Epub 2015/04/25. https://doi.org/10.1186/s13054-015-0918-5 PMID: 25907781.

28. Puskarich MA, Cornelius DC, Tharp J, Nandi U, Jones AE. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. J Crit Care. 2016; 36:125–9. Epub 2016/11/05. https://doi.org/10.1016/j.jcrc.2016.06.027 PMID: 27546760.

29. Ando Y, Okada H, Takemura G, Suzuki K, Takada C, Tomita H, et al. Brain-Specific Ultrastructure of Capillary Endothelial Glycocalyx and Its Possible Contribution for Blood Brain Barrier. Sci Rep. 2018; 8 (1):17523. Epub 2018/12/07. https://doi.org/10.1038/s41598-018-35976-2 PMID: 30504908.

30. Tromp J, van der Pol A, Klip IT, de Boer RA, Jaarsma T, van Gilst WH, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014; 7(3):457–62. Epub 2014/03/22. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000846 PMID: 24647119.

31. Mitic VT, Stojanovic DR, Delijanin Ilic MZ, Stojanovic MM, Petrovic DB, Ignjatovic AM, et al. Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction. Tohoku J Exp Med. 2020; 250(4):233–42. Epub 2020/04/17. https://doi.org/10.1620/tjem.250.233 PMID: 32295985.
32. Machin DR, Bloom SI, Campbell RA, Phuong TTT, Gates PE, Lesniewski LA, et al. Advanced age results in a diminished endothelial glyocalyx. Am J Physiol Heart Circ Physiol. 2018; 315(3):H531–H9. Epub 2018/05/12. https://doi.org/10.1152/ajpheart.00114.2018 PMID: 29750566.

33. Oda K, Okada H, Suzuki A, Tomita H, Kobayashi R, Sumi K, et al. Factors Enhancing Serum Syndecan-1 Concentrations: A Large-Scale Comprehensive Medical Examination. J Clin Med. 2019; 8(9). Epub 2019/08/30. https://doi.org/10.3390/jcm8091320 PMID: 31462009.

34. Liborio AB, Braz MB, Seguro AC, Meneses GC, Neves FM, Pedrosa DC, et al. Endothelial glyocalyx damage is associated with leptospirosis acute kidney injury. Am J Trop Med Hyg. 2015; 92(3):611–6. Epub 2015/01/28. https://doi.org/10.4269/ajtmh.14-0232 PMID: 25624405.

35. Padberg JS, Wiesinger A, di Marco GS, Reuter S, Grabner A, Kentrup D, et al. Damage of the endothelial glyocalyx in chronic kidney disease. Atherosclerosis. 2014; 234(2):335–43. Epub 2014/04/15. https://doi.org/10.1016/j.atherosclerosis.2014.03.016 PMID: 24727235.

36. Suzuki K, Okada H, Sumi K, Tomita H, Kobayashi R, Ishihara T, et al. Serum syndecan-1 reflects organ dysfunction in critically ill patients. Sci Rep. 2021; 11(1):8864. Epub 2021/04/25. https://doi.org/10.1038/s41598-021-88303-7 PMID: 33893369.

37. Burke-Gaffney A, Evans TW. Lest we forget the endothelial glycocalyx in sepsis. Crit Care. 2012; 16(2):121. Epub 2012/04/13. https://doi.org/10.1186/cc11339 PMID: 22494667.

38. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964; 2(5402):177. Epub 1964/07/18. https://doi.org/10.1136/bmj.2.5402.177 PMID: 14150898.

39. Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol. 2010; 26:89–114. https://doi.org/10.1146/annurev-cellbio-100109-104126 PMID: 20565253.

40. Lambaerts K, Wilcox-Adelman SA, Zimmermann P. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol. 2009; 21(5):662–9. Epub 2009/06/19. https://doi.org/10.1016/jceb.2009.05.002 PMID: 19535238.

41. Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle. 2014; 5(1):1–3. Epub 2014/01/31. https://doi.org/10.1152/ajpheart.00104.2013 PMID: 24595459.

42. Maciejewski TE, Verdecchia P, Carini G, Circo A, Giovannini E, Lombardo M, et al. Left ventricular mass and pulmonary capillary endothelial glycocalyx during endotoxemia. Chest. 2018; 154(2):317–25. Epub 2018/03/21. https://doi.org/10.1016/j.chest.2018.03.003 PMID: 29555594.

43. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358(25):2667–77. Epub 2008/06/21. https://doi.org/10.1056/NEJMoa0708789 PMID: 18565859.

44. Manon-Jensen T, Itch Y, Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 2010; 277(19):3876–89. Epub 2010/09/16. https://doi.org/10.1111/j.1742-4658.2010.07798.x PMID: 20840585.

45. Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012; 31(1):3–16. Epub 2011/10/29. https://doi.org/10.1016/j.matbio.2011.10.001 PMID: 22033227.

46. Verdecchia P, Carini G, Circo A, Giovannini E, Lombardo M, et al. Left ventricular mass and pulmonary capillary endothelial glycocalyx during endotoxemia. Chest. 2018; 154(2):317–25. Epub 2018/03/21. https://doi.org/10.1016/j.chest.2018.03.003 PMID: 29555594.

47. Schellings MW, Vanhoutte D, van Almen GC, Swinnen M, Leenders JJ, Kubben N, et al. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension. 2010; 55(2):249–56. Epub 2010/01/06. https://doi.org/10.1161/HYPERTENSIONAHA.109.137885 PMID: 20048198.

48. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998; 32(5):1454–9. Epub 1998/11/21. https://doi.org/10.1016/s0735-1097(98)00407-0 PMID: 9809962.

49. Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezzu A Jr., Orlandini A, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015; 386(9990):266–73. Epub 2015/04/07. https://doi.org/10.1016/S0140-6736(14)62000-6 PMID: 25982160.

50. Huo Y, Wassab GS. Effect of compliance and hematocrit on wall shear stress in a model of the entire coronary arterial tree. J Appl Physiol (1985). 2009; 107(2):500–5. Epub 2009/06/23. https://doi.org/10.1152/japplphysiol.91013.2008 PMID: 19541733.

51. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A. 1995; 92(24):11190–4. Epub 1995/11/21. https://doi.org/10.1073/pnas.92.24.11190 PMID: 7479963.